Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 30, 2026
TickeronGET DAILY SIGNALS
enVVeno Medical (NVNO) Q3 2026 Update: Narrower Loss and Steady Cash Runway

enVVeno Medical (NVNO) Q3 2026 Update: Narrower Loss and Steady Cash Runway

Key Takeaways

  • enVVeno Medical reported a third-quarter 2026 net loss of $4.4 million, or $6.29 per share, compared with a net loss of $4.5 million, or $7.89 per share, in the same period last year.
  • Total operating expenses came in at $4.5 million, down from $4.9 million a year earlier, even as the company prepared to launch its pivotal clinical study.
  • The company ended the quarter with $18.5 million in cash and investments and reiterated that its resources are expected to fund operations into the fourth quarter of 2027.
  • Quarterly cash burn was approximately $3 million, and management expects the burn rate to rise to between $4 million and $5 million per quarter in the first half of 2027 as patient enrollment accelerates.
  • enVVeno remains a pre-revenue, clinical-stage company, making its regulatory and clinical milestones the primary drivers of shareholder value rather than top-line results.

Why Quarterly Results Matter for NVNO

For a clinical-stage medical device company like NVNO, earnings reports focus less on revenue and more on cash runway, expense control, and progress toward key regulatory steps. The company is developing the enVVe System, a first-in-class, non-surgical replacement venous valve for patients with severe deep chronic venous insufficiency (CVI), a condition affecting roughly 3 million people in the U.S. After receiving an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) earlier in 2026, enVVeno is preparing to enroll its first patients in the TAVVE pivotal study. This quarter’s update is worth reviewing because it shows whether the company has the capital and operational footing to move a potentially important therapy forward. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Breaking Down the Reported Numbers

enVVeno Medical reported a net loss of $4.4 million for the third quarter ended September 30, 2026, or $6.29 per basic and diluted share. That compares with a net loss of $4.5 million, or $7.89 per share, in the third quarter of 2025. The company remains pre-revenue, so there were no product sales. Total operating expenses totaled $4.5 million, down from $4.9 million in the prior-year quarter, which points to disciplined cost management while the team readied the TAVVE study. Cash burn for the quarter was about $3 million. As of September 30, 2026, enVVeno held roughly $18.5 million in cash and investments, including $2.6 million in cash and cash equivalents plus $15.9 million in short-term investments. Management noted that these resources should support operations into the fourth quarter of 2027.

Market Reaction and Investor Focus

Investor attention around the earnings has stayed on the company’s path toward starting patient enrollment in the TAVVE pivotal study rather than the income statement itself. Management indicated that clinical sites are being activated and that the first patient enrollment remains on track before year-end. This milestone, along with an earlier analyst upgrade and a $30 price target from Ladenburg, keeps sentiment centered on execution rather than near-term profits. Because NVNO is still pre-revenue, any delays in study timelines or unexpected capital needs could pressure the stock, while successful early enrollment could support confidence in the enVVe System’s potential. From what I see, the market is pricing in these clinical steps more than quarterly financial details.

Forward Outlook and Factors to Watch

The nearest catalyst is the start of Part 1 of the TAVVE pivotal study, expected to enroll up to 10 patients whose 30-day safety data will go to the FDA. After that review, the company plans to advance into Part 2, a randomized stage with 220 patients — 165 receiving the enVVe System and 55 in a control arm. Investors should track the pace of site activation and enrollment, since delays could stretch timelines and affect the cash position. Management expects quarterly cash burn to move to between $4 million and $5 million in the first half of 2027 as the study advances. Longer term, the goal is to submit a premarket approval (PMA) application to the FDA after 12-month follow-up on the randomized stage. Key items to monitor include operating expense trends, any financing activity, and early safety and efficacy data. These steps carry real clinical and regulatory risk, and there is no assurance the enVVe System will receive FDA approval. I’m watching this closely as the study gets underway.

Using Tickeron’s AI Tools in My Research

When I evaluate clinical-stage names like this, I find it helpful to run additional screens for context on sector trends and comparable companies. Tickeron’s AI Screener lets me quickly filter for relevant healthcare stocks and technical signals, which adds another layer to the fundamental review without replacing it. The platform’s customizable options for industry, market cap, and performance metrics make it straightforward to spot patterns across the space.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: NVNO

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


NVNO sees MACD Histogram crosses below signal line

NVNO saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 16, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 48 instances where the indicator turned negative. In 44 of the 48 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVNO as a result. In 79 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVNO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for NVNO entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVNO advanced for three days, in 193 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

NVNO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.226) is normal, around the industry mean (4.142). P/E Ratio (-0.270) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. NVNO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVNO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalNursingServices

Industry
N/A
Address
70 Doppler
Phone
+1 949 261-2900
Employees
33
Web
https://www.envveno.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.
enVVeno Medical (NVNO) Q3 2026 Update: Narrower Loss and Steady Cash Runway